Lysine pathway metabolites and the risk of type 2 diabetes and cardiovascular disease in the PREDIMED study: results from two case-cohort studies
Background The pandemic of cardiovascular disease (CVD) and type 2 diabetes (T2D) requires the identification of new predictor biomarkers. Biomarkers potentially modifiable with lifestyle changes deserve a special interest. Our aims were to analyze: (a) The associations of lysine, 2-aminoadipic acid...
| Autores: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2019 |
| País: | España |
| Institución: | Conselleria de Salut i Consum del Govern de les Illes Balears |
| Repositorio: | Docusalut |
| Idioma: | inglés |
| OAI Identifier: | oai:docusalut.com:20.500.13003/13075 |
| Acceso en línea: | https://hdl.handle.net/20.500.13003/13075 |
| Access Level: | acceso abierto |
| Palabra clave: | Aged, 80 and over Diabetes Mellitus, Type 2 Cardiovascular Diseases Humans Lysine Risk Reduction Behavior Middle Aged Male Risk Assessment Biomarkers Prospective Studies Time Factors Female Risk Factors Treatment Outcome Pipecolic Acids 2-Aminoadipic Acid Randomized Controlled Trials as Topic Aged Primary Prevention Incidence Diet, Mediterranean Ácido 2-Aminoadípico Dieta Mediterránea Incidencia Resultado del Tratamiento Biomarcadores Factores de Tiempo Femenino Conducta de Reducción del Riesgo Masculino Factores de Riesgo Humanos Persona de Mediana Edad Ácidos Pipecólicos Estudios Prospectivos Lisina Anciano Medición de Riesgo Anciano de 80 o más Años Diabetes Mellitus Tipo 2 Prevención Primaria Enfermedades Cardiovasculares Ensayos Clínicos Controlados Aleatorios como Asunto Metabolites Cardiovascular disease Type 2 diabetes Dietary intervention |
| Sumario: | Background The pandemic of cardiovascular disease (CVD) and type 2 diabetes (T2D) requires the identification of new predictor biomarkers. Biomarkers potentially modifiable with lifestyle changes deserve a special interest. Our aims were to analyze: (a) The associations of lysine, 2-aminoadipic acid (2-AAA) or pipecolic acid with the risk of T2D or CVD in the PREDIMED trial; (b) the effect of the dietary intervention on 1-year changes in these metabolites, and (c) whether the Mediterranean diet (MedDiet) interventions can modify the effects of these metabolites on CVD or T2D risk. Methods Two unstratified case-cohort studies nested within the PREDIMED trial were used. For CVD analyses, we selected 696 non-cases and 221 incident CVD cases; for T2D, we included 610 non-cases and 243 type 2 diabetes incident cases. Metabolites were quantified using liquid chromatography-tandem mass spectrometry, at baseline and after 1-year of intervention. Results In weighted Cox regression models, we found that baseline lysine (HR+1 SD increase = 1.26; 95% CI 1.06-1.51) and 2-AAA (HR+1 SD increase = 1.28; 95% CI 1.05-1.55) were both associated with a higher risk of T2D, but not with CVD. A significant interaction (p = 0.032) between baseline lysine and T2D on the risk of CVD was observed: subjects with prevalent T2D and high levels of lysine exhibited the highest risk of CVD. The intervention with MedDiet did not have a significant effect on 1-year changes of the metabolites. Conclusions Our results provide an independent prospective replication of the association of 2-AAA with future risk of T2D. We show an association of lysine with subsequent CVD risk, which is apparently diabetes-dependent. No evidence of effects of MedDiet intervention on lysine, 2-AAA or pipecolic acid changes was found. Trial registration ISRCTN35739639; registration date: 05/10/2005; recruitment start date 01/10/2003 |
|---|